DOCSLIB.ORG

Repaglinide Case Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Repaglinide Case Study High-Resolution Mass Spectrometry for Rapid Metabolite Characterization and Reaction Phenotyping: A Case Study with Repaglinide Joanna E. Barbara, Sylvie Kandel, Forrest Stanley and David B. Buckley A DIVISION OF XenoTech, LLC, 16825 W 116th St, Lenexa, KS, USA Introduction Tables and Figures Assessing the involvement of specific cytochrome P450 (P450) enzymes in biotransformation of a drug is an important step in evaluating overall disposition and victim potential for clinically-relevant drug-drug interactions.1 Table 1. Accurate mass metabolite profile for repaglinide (1 or 10 µM) incubated with NADPH-fortified human liver microsomes (0.1 or 0.5 mg/mL) for up to 30 min Figure 4. Effect of preincubation (30 min) of NADPH-fortified human liver microsomes (0.1 mg/mL) with the CYP3A4 inhibitor mibefradil (1 µM) and the CYP2C8 Current methods for biotransformation pathway identification (reaction phenotyping) rely on prior knowledge of inhibitor gemfibrozil glucuronide (100 µM) on formation of five established metabolites, biotransformation routes, and availability of metabolite reference standards or radioisotopically- Retention Time Experimental Mass shift from Proposed elemental Theoretical Mass error Identity Proposed biotransformation metabolites formed from repaglinide (10 µM) incubated for 30 min labeled drug. Synthesis of metabolite standards and radiolabeled compounds is time-consuming and expensive (min) m/z repaglinide composition m/z (ppm) a and the material is typically not available in early preclinical testing. Reaction phenotyping can be achieved by M0-OH 5.48 469.2693 +15.9940 C27H36N2O5 469.2702 -1.9 Hydroxylation 100 No inhibitor monitoring loss of the parent drug, but that approach suffers from a lack of specificity. Consequently, it is C1 5.94 451.2590 -2.0156 C27H34N2O4 451.2597 -0.2 Dehydrogenation preferable to monitor the formation of one or more metabolites to obtain a comprehensive biotransformation C2 6.83 441.2369 -12.0384 C25H32N2O5 441.2389 4.7 O-Deethylation + hydroxylation 90 a ) Mibefradil M4 7.50 469.2700 +15.9947 C27H36N2O5 469.2702 -0.4 Hydroxylation 80 map for the drug of interest. In general, this requires radiolabeled drug or metabolite reference standard % a ( M1 7.95 385.2112 -68.0641 C22H28N2O4 385.2127 -3.9 N,N-Didealkylation material, potentially adding several months to the drug development timeline before biotransformation pathway l a C H N O O-Deethylation o 70 Gemfibrozil M5 8.26 425.2436 -28.0317 25 32 2 4 425.2440 -4.5 r assignments can be made. t glucuronide Repaglinide 8.98 453.2738 -0.0015 C27H36N2O4 453.2753 -3.3 Not applicable n 60 o c C3 10.09 471.2848 +18.0095 C27H38N2O5 471.2859 -0.9 Hydroxylation + reduction f 50 High-resolution mass spectrometry (HRMS) is a powerful tool for a priori metabolite profiling and characteriza- a o M2 10.30 485.2642 +31.9889 C27H36N2O6 485.2652 -5.1 N-Dealkylation + oxidation to the carboxylic acid e tion because complex data sets comprising information on all of the components in a sample, within a specified C4 16.09 451.2583 -2.0170 C27H34N2O4 451.2597 -3.1 Dehydrogenation g 40 2 a mass range, are acquired. HRMS data can be employed for relative quantitation of all detected components C5 17.23 451.2591 -2.0162 C27H34N2O4 451.2597 -1.3 Dehydrogenation t n 30 and have potential for derivation of earlier stage reaction phenotyping information without the need for C H N O Dehydrogenation e C6 17.52 451.2599 -2.0154 27 34 2 4 451.2597 0.4 c a r 20 metabolite reference standards. In the present study, the prandial glucose regulator repaglinide was incubated Corresponds to a metabolite previously established in the literature e with various in vitro reaction phenotyping test systems, and the samples were analyzed by HRMS metabolite P 10 profiling approaches to characterize all of the repaglinide metabolites formed. Relative amounts of each 0 individual metabolite detected in different incubation test systems were compared to establish relationships M0-OH M1 M2 M4 M5 between specific P450 enzymes and repaglinide metabolites. In the absence of metabolite reference standards, Table 2. Comparison of cytochrome P450 enzymes identified with full scan accurate mass spectrometry and relative quantitation CYP2C8 CYP3A4 Unclea r CYP2C8 CYP3A4 the abundance values were not compared across different metabolites since ionization efficiency for each as contributing to repaglinide biotransformation with enzyme involvement established with traditional methods metabolite is unknown. The approach was assessed for its suitability for rapid determination of specific biotransformation pathways for a drug in development without the additional time and cost associated with M0-OH M1 M2 M4 M5 generating radiolabeled drug or metabolite reference standards. CYP2C8, Recombinant P450 enzyme Minor contribution CYP2C8, CYP3A4 CYP3A4 CYP2C8 CYP3A4 Figure 5. Biotransformation scheme for repaglinide established with the high-resolution mass spectrometry experiment from CYP3A4 relative quantitation approach Correlation experiment with OH CYP2C8 CYP3A4 CYP3A4 CYP2C8 CYP3A4 CH O Materials and Methods human liver microsome panel 3 H3C O CH3 Chemical inhibition in human NH O CYP2C8 CYP3A4 CYP2C8, CYP3A4 CYP2C8 CYP3A4 liver microsomes N Repaglinide was purchased from Toronto Research Chemicals (Ontario, Canada). Human liver microsomes Overall conclusion CYP2C8 CYP3A4 CYP2C8, CYP3A4 CYP2C8 CYP3A4 Repaglinide (HLM; n=1 or n=200) were prepared and characterized in-house. Recombinant cytochrome P450 enzymes CYP2C8 3 CYP3A4 3,4 CYP2C8 3,4, CYP3A4 3,4 CYP2C8 3,4 co-expressed with reductase were purchased from Cypex (Dundee, Scotland). 3 Hydroxylation (CYP2C8) Literature Minor contribution Minor contribution Aldehyde Minor contribution CYP3A4 N-dealkylation (CYP3A4) O-deethylation (CYP3A4) 3 3 4 3 OH OH OH from CYP3A4 from CYP2C8 dehydrogenase from CYP3A4 OH CH3 O CH3 O CH3 O Repaglinide (1 or 10 µM) was incubated for up to 30 min (37°C; pH 7.4) with NADPH-fortified HLM (0.1 or 0.5 3 CH O Bidstrup et al (2003) 3 HO H3C O CH3 H3C O CH3 H3C OH 4 mg protein/mL; pooled or from individual donors) or recombinant enzymes, namely CYP1A2, 2B6, 2C8, 2C9, Säll et al (2012) H3C O CH3 NH O NH O NH O 2C19, 2D6, 3A4, or 2J2 (10 pmol/mL). For the inhibition experiments, pooled HLM were pre-incubated with NH O N N N mibefradil (1 µM) or gemfibrozil glucuronide (100 µM), metabolism-dependent inhibitors of CYP3A4 and NH O HO CYP2C8, respectively, for 30 min before incubation with repaglinide. Following protein precipitation with Not detected M4 M0-OH M5 acetonitrile, all samples were analyzed for metabolite profiling with reverse-phase gradient ultra-performance LC and HRMS on a Waters Synapt G2 HDMS quadrupole time of flight mass spectrometer equipped with a Waters Figure 1. Representative plots showing relative abundance changes with time for M1 formed Figure 3. Variation in formation of M0-OH (a,b), M1 (c,d), M2 (e,f), Reduction (reductases/P450) N-dealkylation (CYP3A4) OH Acquity LC (Milford, MA). An unrelated internal standard (1’-hydroxymidazolam) was employed for relative from repaglinide incubated at (a) 1 µM and (b) 10 µM and M4 formed from repaglinide M4 (g,h) and M5 (i,j) with measured CYP2C8 and OH CH O incubated at (c) 1 µM and (d) 10 µM with NADPH-fortified HLM (0.1 and 0.5 mg/mL) for CYP3A4 activity. Data correspond to repaglinide (10 µM) 3 CH3 O quantitation. H C O CH up to 30 min incubated with NADPH-fortified human liver microsomes 3 3 H3C O CH3 (0.1 mg/mL) for 20 min NH O NH O NH OH Metabolites were separated on a Waters Acquity BEH column (1.7 µm, 2.1 x 100 mm) at 50°C with 0.1% formic (a) (b) NH2 Potentially C3 M1 acid in water or acetonitrile (0.4 mL/min) using the following gradient: 10% organic held for 1 min, increased to 0.014 0.14 1.00 (a) 0.90 (b) M1 0.1 mg/mL M1 0.90 0.80 0.1 mg/mL M0-OH M0-OH Oxidation (reductases/P450) 35% at 7 min, 42% at 12 min, 73% at 20 min, and 90% at 25 min. The mass spectrometer was operated in 0.012 0.12 0.80 0.70 o o i 0.5 mg/mL i OH 0.5 mg/mL t 0.70 E t a 0.60 a r o positive, resolution elevated energy mass spectrometry (MS ) or MSMS mode with electrospray ionization. All o r 0.01 0.1 0.60 ti ti 0.50 CH3 O a E a ea 0.50 ea r r r r samples were analyzed with full scan MS . The low energy scan data were employed for quantitation. Generic a a a a 0.40 0.008 0.08 0.40 H3C O CH3 e e r r 0.30 a a 0.30 eak ionization parameters were used throughout. Fexofenadine was employed for real-time mass calibration. Data eak NH O O k k P 0.006 0.06 0.20 P a a 0.20 e processing employed MetaboLynx XS and QuanLynx subroutines of Waters MassLynx version 4.1 (Milford, MA). e 0.10 P P r = 0.967 0.10 NH OH 0.004 0.04 0.00 r = 0.569 0.00 Metabolite structural elucidation was performed manually. 0 100 200 300 400 500 M2 0.002 0.02 0 2000 4000 6000 8000 1 µM 10 µM CYP2C8 0 0 CYP3A4/5 (pmol/mg/min) (pmol/mg/min) 0 10 20 30 0 10 20 30 Time (min) Time (min) 0.08 (c) 0.09 (d) Results 0.07 M1 0.08 M1 0.07 o o 0.06 i (c) (d) i t t 0.06 a a r 0.05 r 6.00 Conclusion 0.70 0.05 ea E 0.1 mg/mL 0.04 ea r 0.1 mg/mL M4 M4 r a a 0.04 Eleven repaglinide metabolites were characterized by full scan accurate MS in the HLM incubations as 0.60 5.00 0.03 3,4 0.5 mg/mL 0.5 mg/mL 0.03 eak summarized in Table 1.
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Inhibition of Cytochrome P450 2C8-Mediated Drug Metabolism by the Flavonoid Diosmetin
    Drug Metab. Pharmacokinet. 26 (6): 559­568 (2011). Copyright © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Regular Article Inhibition of Cytochrome P450 2C8-mediated Drug Metabolism by the Flavonoid Diosmetin Luigi QUINTIERI1,PietroPALATINI1,StefanoMORO2 and Maura FLOREANI1,* 1Department of Pharmacology and Anaesthesiology, University of Padova, Italy 2Molecular Modeling Section (MMS), Department of Pharmaceutical Sciences, University of Padova, Italy Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Summary: The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6¡-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6¡-hydroxy- paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC50 values 4.25 « 0.02 and 68.5 « 3.3 µM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, we characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (Ki)being3.13« 0.11 µM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the Vmax (maximum velocity) and increased the Km value (substrate concentration yielding 50% of Vmax) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co- administered drugs metabolized by this CYP.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Time-Dependent Inhibition of CYP2C8 and CYP2C19 by Hedera Helix Extracts, a Traditional Respiratory Herbal Medicine
    molecules Article Time-dependent Inhibition of CYP2C8 and CYP2C19 by Hedera helix Extracts, A Traditional Respiratory Herbal Medicine Shaheed Ur Rehman 1, In Sook Kim 2, Min Sun Choi 2, Seung Hyun Kim 3, Yonghui Zhang 4 and Hye Hyun Yoo 2,* 1 Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan; [email protected] 2 Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do 15588, Korea; [email protected] (I.S.K.); [email protected] (M.S.C.) 3 College of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon 21983, Korea; [email protected] 4 School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China; [email protected] * Correspondence: [email protected]; Tel.: +82-31-400-5804; Fax: +82-31-400-5958 Received: 1 June 2017; Accepted: 20 July 2017; Published: 24 July 2017 Abstract: The extract of Hedera helix L. (Araliaceae), a well-known folk medicine, has been popularly used to treat respiratory problems, worldwide. It is very likely that this herbal extract is taken in combination with conventional drugs. The present study aimed to evaluate the effects of H. helix extract on cytochrome P450 (CYP) enzyme-mediated metabolism to predict the potential for herb–drug interactions. A cocktail probe assay was used to measure the inhibitory effect of CYP. H. helix extracts were incubated with pooled human liver microsomes or CYP isozymes with CYP-specific substrates, and the formation of specific metabolites was investigated to measure the inhibitory effects.
    [Show full text]
  • Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population
    Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Halling, Jónrit, Maria S. Petersen, Per Damkier, Flemming Nielsen, Philippe Grandjean, Pál Weihe, Stefan Lundgren, Mia Sandberg Lundblad, and Kim Brøsen. 2005. “Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population.” European Journal of Clinical Pharmacology 61 (7) (July 16): 491–497. doi:10.1007/s00228-005-0938-1. Published Version doi:10.1007/s00228-005-0938-1 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34786606 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA POLYMORPHISM OF CYP2D6, CYP2C19, CYP2C9 AND CYP2C8 IN THE FAROESE POPULATION Jónrit Halling1, Maria S. Petersen2, Per Damkier3, Flemming Nielsen1,2 , Philippe Grandjean2, Pál Weihe4, Stefan Lundgren5, Mia Sandberg Lundblad5 and Kim Brøsen1 1 Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Winslovparken 19, 5000 Odense C, Denmark. 2 Institute of Public Health, Enviromental Medicine, University of Southern Denmark, Winslovparken 17, 5000 Odense C, Denmark. 3Department KKA, Clinical Pharmacology, Odense University Hospital, Odense, Denmark 4 The Faroese Hospital System, Department of Occupational
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]
  • Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling
    International Journal of Molecular Sciences Article Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling William R. Arnold 1 , Susan Zelasko 1, Daryl D. Meling 1, Kimberly Sam 1 and Aditi Das 1,2,3,4,* 1 Department of Biochemistry, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA; [email protected] (W.R.A.); [email protected] (S.Z.); [email protected] (D.D.M.); [email protected] (K.S.) 2 Department of Comparative Biosciences, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA 3 Department of Bioengineering, University of Illinois Urbana-Champaign, Beckman Institute for Advanced Science and Technology, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA 4 Division of Nutritional Sciences, University of Illinois Urbana-Champaign, 3813 Veterinary Medicine Basic Sciences Building, 2001 South Lincoln Avenue, Urbana, IL 61802, USA * Correspondence: [email protected]; Tel.: +1217-244-0630 Received: 30 August 2019; Accepted: 13 September 2019; Published: 18 September 2019 Abstract: Cytochrome P450 2C8 (CYP2C8) epoxygenase is responsible for the metabolism of over 60 clinically relevant drugs, notably the anticancer drug Taxol (paclitaxel, PAC). Specifically, there are naturally occurring polymorphisms, CYP2C8*2 and CYP2C8*3, that display altered PAC hydroxylation rates despite these mutations not being located in the active site. Herein, we demonstrate that these polymorphisms result in a greater uncoupling of PAC metabolism by increasing the amount of hydrogen peroxide formed per PAC turnover.
    [Show full text]
  • Chapter I Introduction
    LI, TIANGANG, Ph.D., May, 2006 BIOMEDICAL SCIENCES PREGNANE X RECEPTOR REGULATION OF BILE ACID METABOLISM AND CHOLESTEROL HOMEOSTASIS (189 PP.) Director of Dissertation: John Y. L. Chiang, Ph.D The nuclear receptor pregnane X receptor (PXR) is activated by bile acids, steroids and drugs and regulates a network of genes in lipid and drug mechanisms. The goal of this study is to investigate the role of PXR in the coordinate regulation of bile acid synthetic and detoxification genes and its implications in cholestatic liver diseases and treatments. Cholesterol 7α hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic bile acids synthetic pathway and plays a key role in controlling bile acids homeostasis. Quantitative real-time PCR (Q-PCR) showed human PXR agonist rifampicin inhibited CYP7A1 mRNA expression in primary human hepatocytes. Mammalian two-hybrid assays, co-immunoprecipitation (co-IP) assays and chromatin immunoprecipitation (ChIP) assay revealed that ligand-activated PXR strongly interacted with HNF4α, the key activator of human CYP7A1, and blocked HNF4α interaction with co-activator PGC-1α, thus resulted in inhibition of CYP7A1. CYP3A4 is the most abundant cytochrome P450 monooxygenase expressed in human liver and intestine. Bile acids and drugs-activated PXR induces CYP3A4, which converts toxic bile acids to non-toxic metabolites for excretion. Studies using Q-PCR, reporter assays, GST pull-down assays and ChIP assays revealed that PXR strongly induced CYP3A4 gene transcription by interacting with HNF4α, SRC-1 and PGC-1α. SHP, a negative nuclear receptor, reduced PXR recruitment of HNF4α and SRC-1 to the CYP3A4 chromatin and inhibited CYP3A4.
    [Show full text]
  • Animal Models to Study Bile Acid Metabolism T ⁎ Jianing Li, Paul A
    BBA - Molecular Basis of Disease 1865 (2019) 895–911 Contents lists available at ScienceDirect BBA - Molecular Basis of Disease journal homepage: www.elsevier.com/locate/bbadis ☆ Animal models to study bile acid metabolism T ⁎ Jianing Li, Paul A. Dawson Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Emory University, Atlanta, GA 30322, United States ARTICLE INFO ABSTRACT Keywords: The use of animal models, particularly genetically modified mice, continues to play a critical role in studying the Liver relationship between bile acid metabolism and human liver disease. Over the past 20 years, these studies have Intestine been instrumental in elucidating the major pathways responsible for bile acid biosynthesis and enterohepatic Enterohepatic circulation cycling, and the molecular mechanisms regulating those pathways. This work also revealed bile acid differences Mouse model between species, particularly in the composition, physicochemical properties, and signaling potential of the bile Enzyme acid pool. These species differences may limit the ability to translate findings regarding bile acid-related disease Transporter processes from mice to humans. In this review, we focus primarily on mouse models and also briefly discuss dietary or surgical models commonly used to study the basic mechanisms underlying bile acid metabolism. Important phenotypic species differences in bile acid metabolism between mice and humans are highlighted. 1. Introduction characteristics such as small size, short gestation period and life span, which facilitated large-scale laboratory breeding and housing, the Interest in bile acids can be traced back almost three millennia to availability of inbred and specialized strains as genome sequencing the widespread use of animal biles in traditional Chinese medicine [1].
    [Show full text]
  • Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    1521-0081/68/1/168–241$25.00 http://dx.doi.org/10.1124/pr.115.011411 PHARMACOLOGICAL REVIEWS Pharmacol Rev 68:168–241, January 2016 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: MARKKU KOULU Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions Janne T. Backman, Anne M. Filppula, Mikko Niemi, and Pertti J. Neuvonen Department of Clinical Pharmacology, University of Helsinki (J.T.B., A.M.F., M.N., P.J.N.), and Helsinki University Hospital, Helsinki, Finland (J.T.B., M.N., P.J.N.) Abstract ...................................................................................169 I. Introduction . ..............................................................................169 II. Basic Characteristics of Cytochrome P450 2C8 . ..........................................170 A. Genomic Organization and Transcriptional Regulation . ...............................170 B. Protein Structure ......................................................................171 C. Expression .............................................................................172 III. Substrates of Cytochrome P450 2C8. ......................................................173 A. Drugs..................................................................................173 1. Anticancer Agents...................................................................173 Downloaded from 2. Antidiabetic Agents. ................................................................183 3. Antimalarial Agents.................................................................183
    [Show full text]
  • Biodiversity of P-450 Monooxygenase: Cross-Talk
    Cytochrome P450: Oxygen activation and biodiversty 1 Biodiversity of P-450 monooxygenase: Cross-talk between chemistry and biology Heme Fe(II)-CO complex 450 nm, different from those of hemoglobin and other heme proteins 410-420 nm. Cytochrome Pigment of 450 nm Cytochrome P450 CYP3A4…. 2 High Energy: Ultraviolet (UV) Low Energy: Infrared (IR) Soret band 420 nm or g-band Mb Fe(II) ---------- Mb Fe(II) + CO - - - - - - - Visible region Visible bands Q bands a-band, b-band b a 3 H2O/OH- O2 CO Fe(III) Fe(II) Fe(II) Fe(II) Soret band at 420 nm His His His His metHb deoxy Hb Oxy Hb Carbon monoxy Hb metMb deoxy Mb Oxy Mb Carbon monoxy Mb H2O/Substrate O2-Substrate CO Substrate Soret band at 450 nm Fe(III) Fe(II) Fe(II) Fe(II) Cytochrome P450 Cys Cys Cys Cys Active form 4 Monooxygenase Reactions by Cytochromes P450 (CYP) + + RH + O2 + NADPH + H → ROH + H2O + NADP RH: Hydrophobic (lipophilic) compounds, organic compounds, insoluble in water ROH: Less hydrophobic and slightly soluble in water. Drug metabolism in liver ROH + GST → R-GS GST: glutathione S-transferase ROH + UGT → R-UG UGT: glucuronosyltransferaseGlucuronic acid Insoluble compounds are converted into highly hydrophilic (water soluble) compounds. 5 Drug metabolism at liver: Sleeping pill, pain killer (Narcotic), carcinogen etc. Synthesis of steroid hormones (steroidgenesis) at adrenal cortex, brain, kidney, intestine, lung, Animal (Mammalian, Fish, Bird, Insect), Plants, Fungi, Bacteria 6 NSAID: non-steroid anti-inflammatory drug 7 8 9 10 11 Cytochrome P450: Cysteine-S binding to Fe(II) heme is important for activation of O2.
    [Show full text]